Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced， recurrent or metastatic esophageal squamous cell carcinoma

CHEN Qiuping; SHAO Mingyi; ZHANG Rongrong; CHEN Xiaoqi

doi:10.6039/j.issn.1001-0408.2023.03.17

您当前的位置：

首页 >

文章列表页 >

Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced， recurrent or metastatic esophageal squamous cell carcinoma

更新时间：2023-02-22

- Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced， recurrent or metastatic esophageal squamous cell carcinoma
- ZHONGGUO YAOFANG Vol. 34, Issue 3, Pages: 345-349(2023)
- 作者机构：
  
  1.河南中医药大学第一临床医学院，郑州　450046
  2.河南中医药大学第一附属医院消化科，郑州　450000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.03.17
  CLC： R956;R979.1
- Published：15 February 2023，
  
  Received：08 June 2022，
  
  Revised：04 January 2023，
扫描看全文
陈秋平,邵明义,张容容等.信迪利单抗联合化疗方案一线治疗晚期、复发或转移性食管鳞状细胞癌的成本-效用分析 ^Δ[J].中国药房,2023,34(03):345-349.

CHEN Qiuping,SHAO Mingyi,ZHANG Rongrong,et al.Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced， recurrent or metastatic esophageal squamous cell carcinoma[J].ZHONGGUO YAOFANG,2023,34(03):345-349.
陈秋平,邵明义,张容容等.信迪利单抗联合化疗方案一线治疗晚期、复发或转移性食管鳞状细胞癌的成本-效用分析 ^Δ[J].中国药房,2023,34(03):345-349. DOI： 10.6039/j.issn.1001-0408.2023.03.17.

CHEN Qiuping,SHAO Mingyi,ZHANG Rongrong,et al.Cost-utility analysis of sintilimab combined with chemotherapy in first-line treatment of advanced， recurrent or metastatic esophageal squamous cell carcinoma[J].ZHONGGUO YAOFANG,2023,34(03):345-349. DOI： 10.6039/j.issn.1001-0408.2023.03.17.

摘要

目的

从我国卫生体系角度评价信迪利单抗联合化疗方案对比单用化疗方案一线治疗晚期、复发或转移性食管鳞状细胞癌（ESCC）的经济性，为临床合理用药提供参考。

方法

基于ORIENT-15研究数据，使用TreeAge Pro 2011软件建立具有无进展生存（PFS）、疾病进展和死亡三状态的Markov模型进行成本-效用分析，模型周期为3周，研究时限为10年，贴现率为5%。模型输出主要结果为总成本、质量调整生命年（QALY）和增量成本-效果比（ICER）。以1～3倍2021年我国人均国内生产总值（GDP）为意愿支付（WTP）阈值。参数的不确定性采用单因素敏感性分析和概率敏感性分析，并探讨上述2种方案在不同的贴现率、对比其他同类治疗方案和有慈善赠药方案3种情境下的经济性。

结果

基础分析结果显示，与单用化疗方案相比，信迪利单抗联合化疗方案的ICER为64 208.75元/QALY，小于WTP阈值。单因素敏感性分析结果显示，PFS状态效用值、信迪利单抗周期成本和贴现率对结果的影响相对较大。概率敏感性分析结果显示，当WTP阈值≥120 000元时，信迪利单抗联合化疗方案具有经济性的概率为100%。情境分析结果显示，3种情境下的信迪利单抗联合化疗方案均较单用化疗方案更具有经济性。

结论

信迪利单抗联合化疗方案相较于单用化疗方案一线治疗晚期、复发或转移性ESCC更具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of sintilimab combined with chemotherapy than single-use chemotherapy in the first-line treatment of advanced， recurrent or metastatic esophageal squamous cell carcinoma （ESCC） from the perspective of health system of our country， and provide reference for rational use of drug in clinic.

METHODS

Based on ORIENT-15 study data， TreeAge Pro 2011 software was used to establish a three-state Markov model of non-progressive survival （PFS）， disease progression and death for cost-utility analysis. The model period was 3 weeks， the research time limit was 10 years， and the discount rate was 5%. The main outputs of the model were total cost， quality-adjusted life year （QALY） and incremental cost-effectiveness ratio （ICER）. The 1-3 times of China’s GDP per capita in 2021 was taken as the threshold of willing-ness to pay （WTP）. The uncertainty of the parameters was analyzed by single factor sensitivity analysis and probability sensitivity analysis， and the cost-effectiveness of the two schemes was discussed under three situations： different discount rates， comparison with other similar treatment schemes and charitable drug donation schemes.

RESULTS

The results of basic analysis showed that compared with chemotherapy plan alone， the ICER of sintilimab combined with chemotherapy was 64 208.75 yuan/QALY， which was less than WTP threshold. The results of single factor sensitivity analysis show that PFS state utility value， cycle cost of sintilimab and discount rate had relatively great influence on the results. Probability sensitivity analysis showed that when WTP≥120 000 yuan， the economic probability of sintilimab combined with chemotherapy plan was 100%. The results of situational analysis showed that sintilimab combined chemotherapy was more cost-effective than single-use chemotherapy.

CONCLUSIONS

Sintilimab combined with chemotherapy is more cost-effective than single-use chemotherapy in the first-line treatment of advanced， recurrent or metastatic ESCC.

关键词

信迪利单抗食管鳞状细胞癌紫杉醇顺铂成本-效用分析药物经济学

Keywords

esophageal squamous cell carcinomapaclitaxelcisplatincost-utility analysispharmacoeconomics

references

秦静，杨飞，陈谦，等. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报（医学版），2022，60（7）：74-82.

李绪渊，罗何三，王鸿彪，等. 胸段食管鳞癌手术治疗或根治性放化疗后复发和生存分析[J]. 肿瘤防治研究，2017，44（4）：286-289.

MURO K，KOJIMA T，MORIWAKI T，et al. Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer：subgroup analysis from KEYNOTE-181[J]. Esophagus，2022，19（1）：137-145.

WEBER J S，D’ANGELO S P，MINOR D，et al. Ni- volumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment （CheckMate 037）：a randomised，controlled，open-label，phase 3 trial[J]. Lancet Oncol，2015，16（4）：375-384.

朱丹，李月阳，宋燕青，等. PD-1抑制剂信迪利单抗的临床研究进展[J]. 中国医院药学杂志，2020，40（1）：120-123.

LU Z H，WANG J Y，SHU Y Q，et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma （ORIENT-15）：multicentre，randomised，double blind，phase 3 trial[J]. BMJ，2022，377：e068714.

中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）食管癌诊疗指南：2022[M].北京：人民卫生出版社，2022：68-91.

国产首家!信迪利单抗获批一线胃癌适应证，冲刺2022医保谈判[EB/OL]. [2022-06-23]. https：//view.inews.qq.com/k/20220624A0BDEL00?web_channel=wap&openApp=falsehttps://view.inews.qq.com/k/20220624A0BDEL00?web_channel=wap&openApp=false.

王汉华，杭业，王文才，等. 白蛋白紫杉醇联合卡铂方案同步放疗治疗局部晚期食管癌[J]. 中国临床研究，2022，35（3）：330-333.

刘国恩.中国药物经济学评价指南2020[M].北京：中国市场出版社，2020：4-5，19，27-28.

齐冉，杜桂平，刘旭婷，等. 帕博利珠单抗联合化疗一线治疗晚期或转移性食管癌的成本-效用分析[J]. 中国药房，2022，33（12）：1466-1473.

石丰豪，金敏，王子婧，等. 卡瑞利珠单抗对比化疗方案二线治疗晚期或转移性食管鳞状细胞癌的成本效用分析[J]. 中国卫生经济，2021，40（12）：73-77.

胡梦雪，高红婷，宁智鹏，等. 帕博利珠单抗单药与化疗二线治疗晚期或转移性食管癌的成本-效果分析[J]. 中国医院药学杂志，2022，42（3）：318-323.

ZHENG Z W，LIN J R，ZHU H D，et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy vs. chemotherapy alone as first-line treatment in patients with esophageal squamous cell carcinoma and PD-L1 CPS of 10 or more[J]. Front Public Health，2022，10：893387.

石丰豪，商叶，芮明军，等. R语言survHE程序包在卫生经济学评价中的应用[J]. 中国卫生经济，2020，39（9）：9-14.

张颖，曾小慧，万小敏，等. 阿替利珠单抗治疗转移性非小细胞肺癌的成本效用分析[J]. 中国医院药学杂志，2021，41（8）：828-832.

张凌凌，李晓松，高川川，等. 肺炎克雷伯菌的耐药率与抗菌药物使用频度的相关性研究[J]. 系统医学，2021，6（24）：64-68.

沈苗红，施雪菲，季东翔. 肺癌患者化疗后肺部感染的危险因素分析及其预防措施探讨[J]. 中国现代医生，2020，58（24）：100-103.

何慧英. 肿瘤患者化疗过程中的血压变化及护理对策[J]. 护士进修杂志，2003，18（9）：852-853.

杨柳青，陈映霞，秦叔逵，等. 肿瘤抗血管生成药物致高血压的临床观察[J]. 临床肿瘤学杂志，2014，19（7）：603-607.

陈琦玲. 特殊类型高血压临床诊治要点专家建议[J]. 中国全科医学，2020，23（10）：1202-1228.

张晓勤. 高血压治疗中ACEI和ARB的应用[J]. 中国实用医药，2008，3（31）：150-151.

张惠芹，张和平. 《肿瘤化学治疗新进展》《肿瘤内科临床手册》简介[J]. 实用肿瘤学杂志，1987，1（1）：66.

陈良新，孙鹏，胡中舟. 信迪利单抗联合化疗对晚期非小细胞肺癌肿瘤标志物及免疫功能的影响[J]. 检验医学与临床，2022，19（8）：1106-1108.

吴清斌. 信迪利单抗联合TP方案治疗晚期非小细胞肺癌的临床效果[J]. 临床合理用药杂志，2022，15（11）：70-73.

DAI L，CAI X C，MUGAANYI J，et al. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma[J]. Sci Rep，2021，11（1）：19711.

王玉，祝守慧，刘宁，等. 信迪利单抗治疗复发或转移晚期食管癌患者疗效初步观察[J]. 中华肿瘤防治杂志，2020，27（22）：1838-1843.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small-cell lung cancer

Pharmacoeconomics of ivabradine in the treatment of CHF in the context of “Quadruple Therapy”

Study on pharmacoeconomic evaluation of vericiguat in the treatment of heart failure with reduced ejection fraction

Pharmacoeconomic evaluation of sugemalimab consolidation therapy for stage Ⅲ non-small cell lung cancer

Rapid health technology assessment of Aidi injection combined with first-line chemotherapy for non-small cell lung cancer

Related Author

QI Ran

NIE Xuyang

LIU Xuting

GAO Shengnan

LIU Guoqiang

CHEN Congling

WU Han

ZHOU Jie

Related Institution

Dept. of Clinical Pharmacy， the Third Hospital of Hebei Medical University

Dept. of Clinical Pharmacology Research， the Fourth Hospital of Hebei Medical University

Dept. of Pharmacy， Nanjing Drum Tower Hospital

School of Basic Medicine and Clinical Pharmacy， China Pharmaceutical University

Dept. of Cardiology， Nanjing Drum Tower Hospital

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰